Our Latest Thinking
Insight, understanding and new direction
IMS Consulting Group is committed to providing a fresh perspective, unique point of view and deep understanding of the dynamics reshaping healthcare markets around the globe. We combine the best available evidence with innovative thinking and expert interpretation to bring insights for more effective decision making.
Emerging Markets
Compulsory Licensing - Securing IP and Access to Medicine
Compulsory licensing is back in the news. Unlike a decade ago, however, the focus is not on HIV/AIDS treatments but rather access to high-price oncology drugs in emerging markets looking to provide lower cost alternatives. Raja Shankar and team investigate this further. Read more
The Big Sell: Biologics In Emerging Markets
This paper published in Pharmaceutical Executive looks at the complex opportunities and access challenges that face commercialization of biologics in Africa, Asia, and Latin America. Read more
Guiding Principles for Providing Effective Access To Medicines In Emerging Markets
This paper presented at ISPOR shows how markets with better pricing and patient access data systems achieve better access to innovative medicines, and lays out guiding principles for providing effective access to these treatments within the budget constraints. Read more
South East Asia - Pharmerging Landscape
Learn more about the opportunity for MNC and generics firms in the rapidly growing, heterogenous South-East Asian pharmaceutical market. Our Singapore team analyzes the forward outlook for the region and highlights specific growth opportunities. Read more
Healthcare Reform
Model Behaviour
IMSCG Principals Steven Flostrand and Raja Shankar look at the consequences of healthcare reforms across Europe, and identify how companies can successfully manage the new and more challenging healthcare funding environment, with a special focus on partnering and evidence generation. Third and final of a series. Read more
Just Des(s)erts
The second of a three-part series on Pharmaceutical Market Europe, Steven Flostrand and Raja Shankar outline healthcare reform scenarios for different European markets and identify measures that countries should take to escape from the ongoing crisis in healthcare funding. Read more
Turbulent Times
In the first of the three-part series on Pharmaceutical Market Europe, Steven Flostrand examines how the financial crisis and consequent healthcare reforms across Europe are affecting the industry, and classifies markets into three groups: the reactionary, the reforming and the deniers. Read more
Launch Excellence
A New Foundation for Designing Winning Brand Strategies – The Patient Journey Re-envisioned
The years immediately preceding a pharmaceutical product launch are arguably one of the riskiest periods in business and “getting it right” has never been more essential. IMS experts discuss the importance of the patient journey – a powerful framework for understanding the market and patient experience – in driving brand growth. Read more
Portfolio Strategy
Entering The Generics Business in Mature Markets
What do branded companies need to know to win in generics? Waseem Noor and Stefan Lunglmayr offer some answers in this article, originally published in IN VIVO, March 2013. Read more
Launch Excellence IV: a new launch environment
Provides a future-focused perspective on the trends that will drive launch environment in the next five –seven years, and identifies the issues that companies will have to address as they plan for Launch Excellence in tomorrow’s environment. Read more
New Paradigm - Incorporating Access Decisions Into Portfolio Strategy
Our Portfolio Strategy leadership presented this framework for value-based access strategy decisions at the 12th Annual Portfolio and Project Management for Pharma Conference in Barcelona. Learn how product valuation and strategy decisions need to be aligned to the changing market access stakeholders and landscape. Read more
Pricing & Market Access
Pricing & Market Access Outlook: 2012
Join our senior team as they share their perspectives on the key issues in IMSCG’s annual state of play in pricing and market access. Read more
Real World Evidence
RWE Market Impact on Medicines: A Lens for Pharma
IMS Health has developed the most comprehensive view of Real-World Evidence use and supply published to date. To learn how this could reshape your company's approach to evidence. Read more
